US Pharma Tariff Exemption: India Gets Relief On Specialty Drugs, But Patented Medicine Risk Remains

Indian pharmaceutical exporters have received some relief from the latest US tariff framework, with Washington allowing zero-tariff treatment for certain specialty medicines and related pharmaceutical ingredients from eligible countries, including India. However, the exemption is limited to specified categories and does not provide blanket protection to Indian drug exports.

The development comes as the United States moves ahead with a 100% Section 232 tariff on specified patented pharmaceutical products and associated ingredients. The duty is effective from September 29 for companies that are not covered by the earlier implementation date.

What US Pharma Tariff Exemption Means For India

The newly clarified zero-tariff treatment covers a defined set of specialty pharmaceutical products. These include orphan drugs, nuclear medicines, plasma-derived therapies, fertility drugs, cell and gene therapy products, antibody-drug conjugates, certain medical countermeasures and animal-health pharmaceuticals. Associated ingredients used in eligible products can also receive the zero tariff, subject to the prescribed conditions.

India's inclusion in the eligible-jurisdiction list is significant for exporters operating in these specialised segments. However, companies cannot assume that every pharmaceutical shipment from India will automatically receive the benefit. Eligibility depends on the nature of the product, its classification and the conditions specified by the US Commerce Department.

The distinction is particularly important because the Section 232 tariff framework currently does not cover generic pharmaceutical products and their associated ingredients. This means India's large generic-drug export segment is outside the scope of these specific Section 232 tariffs for now.

For Indian pharma companies, the immediate tariff exposure is therefore more relevant to businesses involved in patented medicines, specialised therapies and related pharmaceutical ingredients than to conventional generic-drug exports.

A 100% ad valorem tariff effectively imposes a duty equivalent to the value of the covered imported product, unless a lower rate or exemption applies. Such a duty can significantly alter the economics of exporting patented medicines to the US market.

The US proclamation specifically provides for a 100% tariff on covered patented pharmaceuticals and associated pharmaceutical ingredients, while offering different treatment in certain cases, including products linked to approved onshoring plans and specified trade arrangements.

For exporters, the impact can extend beyond the immediate customs cost. Companies may have to reassess pricing, manufacturing locations, supply-chain structures and investment plans depending on which products fall within the tariff framework.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.